H. Lundbeck A/S (Lundbeck) and Otsuka Pharmaceutical Europe Ltd. (Otsuka) today announced results from the final analysis of a mirror-image study showing statistically significant reductions (p<0.0001) in total psychiatric hospitalisation rates in patients diagnosed with schizophrenia who were switched from oral antipsychotics to Abilify Maintena once-monthly 400 mg – a prolonged-release suspension for intramuscular injection of aripiprazole.1 These findings were presented as a late breaker poster at the 4th Biennial Schizophrenia International Research Society (SIRS) conference in Florence, Italy on April 5–9.
Help employers find you! Check out all the jobs and post your resume.
